A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available

Taking stock of the drug industry, from the lab to the medicine chest

May 8, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available "We're trying to crack this nut of affordability and accessibility," said Boro Dropulić, who heads the Caring Cross nonprofit. By Ed Silverman Opinion: Making the promise of monoclonal antibody therapies available to all Life-saving monoclonal antibodies must be made accessible, affordable, and available to people with compromised immune systems. By Ken McEldowney STAT+ | After gene therapy, two congenitally deaf children hear for the first time Two congenitally deaf children can hear after being treated with a gene therapy, according to new data from an ongoing clinical trial. By Timmy Broderick

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser